Velcade Related Clinical Trials
Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma [Recruiting]
Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma [Active, not recruiting]
Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma [Active, not recruiting]
Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma [Active, not recruiting]
Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy [Completed]
Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) [Active, not recruiting]
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma [Completed]
Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia [Completed]
Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma [Active, not recruiting]
Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma [Completed]
Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer [Completed]
A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma [Suspended]
A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer [Terminated]
A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma [Recruiting]
Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer [Recruiting]
Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients [Recruiting]
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma [Recruiting]
Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia [Active, not recruiting]
Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Recruiting]
Bortezomib With or Without Combination Chemotherapy in Treating Patients With Relapsed or Refractory Lymphoma [Active, not recruiting]
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms [Recruiting]
Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma [Recruiting]
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients [Active, not recruiting]
Velcade in MALT Lymphoma Patients [Completed]
VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma [No longer recruiting]
Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma [Recruiting]
Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma [Recruiting]
Study of Temsirolimus, Topotecan, and Bortezomib [Recruiting]
Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma [Active, not recruiting]
Ph II CHOP+Velcade in Mediastinal LBCL
Study of Velcade and Thalidomide in Patients With Myelodysplasia
A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade(Registered Trademark)), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroi... [Recruiting]
Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease [Recruiting]
Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors
Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma [Recruiting]
Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors [Recruiting]
Panobinostat/Velcade in Multiple Myeloma [Recruiting]
Velcade for Proliferative Lupus Nephritis [Recruiting]
A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia [Recruiting]
Bortezomib With or Without Irinotecan in Treating Patients With Recurrent or Metastatic Head and Neck Cancer [Recruiting]
Pilot Study of Velcadeďż˝ in IgA Nephropathy [Recruiting]
Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone [Recruiting]
Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia [Recruiting]
Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens [Recruiting]
Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia [Recruiting]
Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome [Recruiting]
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma [Recruiting]
A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma [Recruiting]
Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma [Recruiting]
Bortezomib and Reduced Intensity Allogenic Stem Cell Transplantation for Lymphoid Malignancies [Recruiting]
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma [Recruiting]
Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients [Recruiting]
Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia [Recruiting]
Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II [Completed]
Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM [Recruiting]
Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma [Active, not recruiting]
Velcade (Bortezomib) Consolidation After Transplant [Recruiting]
Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma [No longer recruiting]
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) [Recruiting]
Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients [Recruiting]
Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib in Subjects With Relapsed/Refractory Multiple Myeloma [Recruiting]
Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma [Recruiting]
IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma [Recruiting]
Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors [Completed]
Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia [Recruiting]
Study of Bortezomib Combined With ACVBP in Peripheral T-Cell Lymphoma [Recruiting]
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas [Recruiting]
Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer [Terminated]
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants [Recruiting]
Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma [Recruiting]
A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients [Recruiting]
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer [Recruiting]
Bortezomib, Ifosfamide, and Vinorelbine in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy [Suspended]
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus Host Disease [Recruiting]
Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability [Recruiting]
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. [Active, not recruiting]
Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Recruiting]
Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma [Terminated]
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma [No longer recruiting]
Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma [Recruiting]
Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma [No longer recruiting]
Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors [Terminated]
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer [Recruiting]
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer [Recruiting]
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma
Velcade and Dexamethasone in Multiple Myeloma [No longer recruiting]
Study of Combination PS-341 and Thalidomide in Multiple Myeloma [Active, not recruiting]
Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features [Terminated]
Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma [Recruiting]
Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia [No longer recruiting]
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders [Recruiting]
Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer [Suspended]
VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma [No longer recruiting]
Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer [No longer recruiting]
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase [Recruiting]
Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade [Completed]
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas [Recruiting]
Bortezomib, Rituximab, and Combination Chemotherapy in Treating Patients With Mantle Cell Lymphoma [Recruiting]
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma
Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma [Terminated]
|
